Drug Profile
NTM 1634
Alternative Names: BoNT C/D; NTM-1634Latest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; Harvard Medical School; University of California at San Francisco
- Developer National Resilience
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Botulism; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Severe acute respiratory syndrome
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for phase-I development in Botulism(In volunteers) in USA (IV)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(In volunteers) in USA (IV)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(In volunteers) in USA (IV)